Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437163 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTTSHRLMNAL3MBTL1 | |
| SCHEMBL1760870 | 0.80 | ATM (0.52) | ATMALDH1A1TP53MAPTTSHR | |
| SCHEMBL11989193 | 0.78 | CYP3A4 (0.49) | ALDH1A1TSHRNPSR1LMNAMEN1 | |
| SCHEMBL11989196 | 0.74 | MAPT (0.47) | ATMALDH1A1TP53MAPTTSHR | |
| SCHEMBL1472784 | 0.74 | MAPK1 (0.53) | ATMALDH1A1TP53MAPTTSHR | |
| SCHEMBL13560870 | 0.73 | P2RX7 (0.49) | ALDH1A1MAPTTSHRMAPK1NPSR1 | |
| SCHEMBL21783607 | 0.72 | IDH1 (0.52) | ALDH1A1TP53MAPK1LMNAL3MBTL1 | |
| SCHEMBL14435408 | 0.69 | ALDH1A1 (0.49) | ALDH1A1MAPTTSHRNPSR1LMNA | |
| SCHEMBL14062942 | 0.68 | ALOX5 (0.37) | ALDH1A1TP53MAPTMAPK1L3MBTL1 | |
| SCHEMBL2960945 | 0.67 | ALDH1A1 (0.54) | ATMALDH1A1TP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | ATM 3369/4885ALDH1A1 513/4885TP53 1/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | ATM 4610/4885ALDH1A1 591/4885TP53 7/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | ATM 4610/4885ALDH1A1 591/4885TP53 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.